Mallinckrodt PLC (NYSE:MNK) was the target of some unusual options trading on Tuesday. Stock traders acquired 26,282 put options on the company. This represents an increase of approximately 1,506% compared to the typical volume of 1,636 put options.
MNK has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $52.00 price target on shares of Mallinckrodt in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Mallinckrodt from a “sell” rating to a “hold” rating in a research report on Monday, November 6th. Deutsche Bank lowered Mallinckrodt from a “buy” rating to a “hold” rating and decreased their price target for the company from $44.00 to $28.00 in a research report on Tuesday, November 7th. Citigroup lowered Mallinckrodt from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $44.00 to $28.00 in a research report on Tuesday, November 7th. Finally, Wells Fargo & Co lowered Mallinckrodt from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $42.64.
Shares of Mallinckrodt (NYSE MNK) opened at $16.68 on Thursday. Mallinckrodt has a one year low of $15.27 and a one year high of $53.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. The firm has a market capitalization of $1,580.00, a PE ratio of -834.00, a PEG ratio of 0.30 and a beta of 1.04.
Several institutional investors and hedge funds have recently bought and sold shares of the company. LSV Asset Management raised its stake in shares of Mallinckrodt by 24.8% during the 4th quarter. LSV Asset Management now owns 2,621,917 shares of the company’s stock worth $59,150,000 after purchasing an additional 520,697 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Mallinckrodt by 16.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,522,330 shares of the company’s stock worth $94,255,000 after purchasing an additional 360,516 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Mallinckrodt by 2.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,987,196 shares of the company’s stock worth $74,260,000 after purchasing an additional 49,752 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in shares of Mallinckrodt by 45.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,535,583 shares of the company’s stock worth $57,385,000 after purchasing an additional 482,591 shares in the last quarter. Finally, Orbimed Advisors LLC raised its stake in shares of Mallinckrodt by 15.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,472,700 shares of the company’s stock worth $55,035,000 after purchasing an additional 200,000 shares in the last quarter. 97.38% of the stock is owned by institutional investors.
WARNING: “Mallinckrodt Target of Unusually Large Options Trading (MNK)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3229495/mallinckrodt-target-of-unusually-large-options-trading-mnk.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.